United Kingdom · Question · Written question
UIN 18237
Futibatinib
Original
Introduced
5 December 2024
Last action
11 December 2024 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
11 December 2024
Summary
To ask the Secretary of State for Health and Social Care, what funding is available for patients to receive the immunotherapy drug Futibatinib through the NHS; and what criteria his Department uses to determine whether a patient is eligible for any fundin
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
5 December 2024
Written question
To ask the Secretary of State for Health and Social Care, what funding is available for patients to receive the immunotherapy drug Futibatinib through the NHS; and what criteria his Department uses to determine whether a patient is eligible for any fundin
Source: Commons
11 December 2024
Answer
NHS England funds the use of licensed medicines that have been recommended by the National Institute for Health and Care Excellence (NICE). Futibatinib is licensed by the Medicines and Healthcare products Regulatory Agency and has been recommended by the ...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2024-12-05/18237
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1747331
- uk · wq-1747331 · source updated 11 December 2024